Skip to main content
OpenTrials
Completed

NCT Number: NCT02103517

Fish Oil and Cardiovascular Suboptimal Health

The purpose of this study is to determine whether omega-3 fatty acids supplementation are effective in the improvement of suboptimal health status and cardiovascular risk.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Chinese PLA General Hospital, Beijing, Beijing Municipality, China

Loading trial locations.

About this study

The Suboptimal health status questionnaire (SHSQ-25) is used to evaluate the suboptimal health status. The SHSQ-25 includes 25 questions. The score of the SHSQ-25 is from 0 to 100. Suboptimal health status is defined as the SHSQ-25 score above than 35. The higher scores of the SHSQ-25 one gets, the more severity of suboptimal health status he/she has. All participants are asked to fill in the SHSQ-25 before and after the intervention. If the score decreases after the intervention, it means that the suboptimal health status has been improved.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • suboptimal health status, defined as the score of suboptimal health questionnaire ≥35.
  • at least one of cardiovascular risk factors:
  • overweight or obesity, defined as body mass index (BMI) ≥25 kg/m2.
  • systolic blood pressure ≥130 and <140 mmHg and diastolic blood pressure <90 mmHg, or diastolic blood pressure ≥85 and <90 mmHg and systolic blood pressure <140 mmHg
  • fasting plasma glucose ≥100 and <126 mg/dL
  • total cholesterol ≥200 and <240 mg/dL, triglyceride ≥150 and <200 mg/dL, low density lipoprotein-cholesterol ≥130 and <160 mg/dL,and/or high density lipoprotein-cholesterol <40 mg/dL
  • written informed consent

Exclusion criteria

  • history of system diseases, such as cardiovascular diseases, digestive system diseases, diseases of respiratory system, blood and immune system diseases, nervous system diseases, endocrine system diseases, and diseases of the genitourinary system.
  • history of mental illness.
  • pregnant or breastfeeding.
  • use of antihypertensive, antidiabetic, or lipid-lowering drugs within the past two weeks.
  • use of fish oil capsules or other supplements containing omega-3 fatty acids within the past two weeks.
  • allergy or intolerance to fish oil, corn oil, omega-3 fatty acids, or vitamin E.
  • participation in another trial.
  • unable to promise to not use drugs and other fish oils during the study.
  • unable to provide informed written consent.

Treatment and study plan

Omega -3 fatty acids

Dietary Supplement

Each subject assigned to active treatment group will receive 4 g/day capsule of omega-3 fatty acids.

Placebo: Corn oil

Dietary Supplement

Each subject assigned to the control group will receive 4 g/day capsule of corn oil.

Primary outcomes

  1. the improvement of suboptimal health status

    Time frame: three months

    The improvement of suboptimal health status is evaluated by the change of the SHSQ-25 scores after intervention.

  2. the improvement of traditional cardiovascular risk factors

    Time frame: three months

    To investigate the changes of traditional cardiovascular risk factors such as blood pressure, lipids, fasting plasma glucose, and body mass index with three months supplementation of omega-3 fatty acids. Abnormal cardiovascular risk factors are defined according to the Adult Treatment Panel III criteria for metabolic syndromes and the recommendation by the Working Group on Obesity in China. The number of abnormal cardiovascular risk factors for each participant is recorded before and after intervention. If the number decreases after intervention, it means that the traditional cardiovascular risk factors have been improved.

Sponsors and collaborators

Lead sponsor

Chinese PLA General Hospital

Other

Registry information

Official study title

Risk and Prevention Study: Optimisation of the Preventive Strategies and Evaluation of the Efficacy of n-3 Fatty Acids in Subjects at High Cardiovascular Risk and Suboptimal Health Status

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Apr 4, 2014
Registry last updated
Jan 4, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.